Plaque Radiotherapy for Residual or Recurrent Iris Melanoma after Surgical Resection in 32 Cases
Plaque Radiotherapy for Residual or Recurrent Iris Melanoma after Surgical Resection in 32 Cases
复制标题
DOI：
10.1016/j.ophtha.2011.09.039
复制
发表时间：
2012-04-01
期刊：
影响因子：
13.7
通讯作者：
Shields, Jerry A.
中科院分区：
文献类型：
--
作者：
Shah, Sanket U.;Shields, Carol L.;Shields, Jerry A.
目的：评价斑块放射治疗对手术切除术后残留或复发的虹膜黑色素瘤的治疗作用。设计：回顾性，非随机干预病例系列。参与者：我们纳入了32例手术切除术后残留或复发的虹膜黑色素瘤患者。干预：定制设计的碘-125斑块放射治疗。主要结果指标：肿瘤控制、复发、视力差、眼球摘除、转移和放射并发症。有32只眼手术切除后残留（n = 12）或复发（n = 20）虹膜黑色素瘤，用碘-125斑块放射治疗。残留的黑色素瘤是明显的临床3例和组织病理学9斑放疗后平均间隔2个月切除。对于复发病例，从初次肿瘤切除到检测到复发的平均时间间隔为58个月，此时应用斑块放射治疗。对于所有病例，放疗时平均肿瘤基底直径为6 mm（范围，1-13），厚度为2 mm（范围，0.8-4.0）。前房种植26眼（81%），青光眼11眼（34%）。27例（84%）患者就诊时视力良好（20/20-20/50），3例（9%）患者视力中等（20/60-20/150），
Purpose: To evaluate plaque radiotherapy for management of residual or recurrent iris melanoma after surgical resection.Design: Retrospective, nonrandomized interventional case series.Participants: We included 32 patients with residual or recurrent iris melanoma after surgical resection.Intervention: Custom designed iodine-125 plaque radiotherapy.Main Outcome Measures: Tumor control, recurrence, poor visual acuity, enucleation, metastasis, and radiation complications.Results: There were 32 eyes with residual (n = 12) or recurrent (n = 20) iris melanoma after surgical resection that were treated with iodine-125 plaque radiotherapy. The residual melanoma was evident clinically in 3 cases and histopathologically in 9; plaque radiotherapy was delivered at a mean interval of 2 months after resection. For the recurrent cases, the mean interval from initial tumor resection to detection of recurrence was 58 months, at which time plaque radiotherapy was applied. For all cases, the mean tumor basal diameter was 6 mm (range, 1-13) and thickness was 2 mm (range, 0.8-4.0) at the time of radiotherapy. Anterior chamber seeding was present in 26 (81%) eyes and glaucoma in 11 (34%) eyes. Visual acuity at presentation was good (20/20-20/50) in 27 (84%), intermediate (20/60-20/150) in 3 (9%), and poor (